Differences in attitude toward adjuvant chemotherapy between colorectal cancer survivors and the medical staff of Japanese hospitals
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 60549133X | ||
| 003 | CHVBK | ||
| 005 | 20210128100509.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150801xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0772-5 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0772-5 | ||
| 245 | 0 | 0 | |a Differences in attitude toward adjuvant chemotherapy between colorectal cancer survivors and the medical staff of Japanese hospitals |h [Elektronische Daten] |c [Yukiya Narita, Hiroya Taniguchi, Koji Komori, Kenya Kimura, Takashi Kinoshita, Azusa Komori, Motoo Nomura, Shigenori Kadowaki, Daisuke Takahari, Takashi Ura, Masashi Andoh, Kei Muro] |
| 520 | 3 | |a Background: Adding oxaliplatin to fluorouracil-based chemotherapy can improve the survival of patients with stage III colorectal cancer by approximately 20%. Reportedly, cancer patients are much more likely to prefer chemotherapy than medical professionals, although there is only a very small chance of achieving benefits from treatment. However, chronic neurotoxicity may be long lasting after the administration of oxaliplatin-based chemotherapy. This study aimed to evaluate potential side effects and differences in attitude between colorectal cancer patients and medical staff regarding the risk-benefit trade-offs of chemotherapy. Methods: Relapse-free colorectal cancer patients who received adjuvant chemotherapy, doctors, and nurses were surveyed using a questionnaire regarding the side effects of chemotherapy and hypothetical clinical scenarios to quantify gains in the risk of relapse that were deemed necessary to make chemotherapy worthwhile. Results: Responses were obtained from 147 patients, 54 doctors, and 84 nurses. Of these, 39% of patients and 85% of doctors replied that moderate side effects of adjuvant chemotherapy were worthwhile to achieve an absolute gain in the risk of relapse of 10% from a baseline of 40%. More severe side effects, as reported by colorectal cancer patients, were not associated with the larger gains necessary to make treatment worthwhile. Seven percent of patients treated with oxaliplatin, 40% of doctors, and 43% of nurses replied that side effects associated with oxaliplatin-based chemotherapy were severe. Conclusions: Doctors should consider potential heterogeneity in side effects and attitudes regarding the risk-benefit balance of adjuvant chemotherapy, and that patient perspectives should enhance shared decision-making. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Adjuvant chemotherapy |2 nationallicence | |
| 690 | 7 | |a Colorectal cancer |2 nationallicence | |
| 690 | 7 | |a Patients' attitudes |2 nationallicence | |
| 700 | 1 | |a Narita |D Yukiya |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | |
| 700 | 1 | |a Taniguchi |D Hiroya |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | |
| 700 | 1 | |a Komori |D Koji |u Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan |4 aut | |
| 700 | 1 | |a Kimura |D Kenya |u Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan |4 aut | |
| 700 | 1 | |a Kinoshita |D Takashi |u Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan |4 aut | |
| 700 | 1 | |a Komori |D Azusa |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | |
| 700 | 1 | |a Nomura |D Motoo |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | |
| 700 | 1 | |a Kadowaki |D Shigenori |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | |
| 700 | 1 | |a Takahari |D Daisuke |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | |
| 700 | 1 | |a Ura |D Takashi |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | |
| 700 | 1 | |a Andoh |D Masashi |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | |
| 700 | 1 | |a Muro |D Kei |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/4(2015-08-01), 755-760 |x 1341-9625 |q 20:4<755 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0772-5 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0772-5 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Narita |D Yukiya |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Taniguchi |D Hiroya |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Komori |D Koji |u Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kimura |D Kenya |u Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kinoshita |D Takashi |u Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Komori |D Azusa |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nomura |D Motoo |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kadowaki |D Shigenori |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Takahari |D Daisuke |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ura |D Takashi |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Andoh |D Masashi |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Muro |D Kei |u Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/4(2015-08-01), 755-760 |x 1341-9625 |q 20:4<755 |1 2015 |2 20 |o 10147 | ||